SciSparc (SPRC) Stock Price, News & Analysis

Company Overview

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Key Stats

• Today's Range: $0.44 to $0.47
• 50-Day Range: $0.21 to $1.07
• 52-Week Range: $0.20 to $4.29
• Volume: 137,966 shs
• Average Volume: 802,453 shs
• Market Capitalization: $4.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SciSparc Stock Analysis - MarketRank™

SciSparc scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for SciSparc.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

SciSparc has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.90% of the float of SciSparc has been sold short.

Short Interest Ratio / Days to Cover

SciSparc has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SciSparc has recently decreased by 32.73%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SciSparc does not currently pay a dividend.

Dividend Growth

SciSparc does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.90% of the float of SciSparc has been sold short.

Short Interest Ratio / Days to Cover

SciSparc has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SciSparc has recently decreased by 32.73%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.08

News Sentiment

SciSparc has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for SciSparc this week, compared to 1 article on an average week.

MarketBeat Follows

Only 1 people have added SciSparc to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, SciSparc insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.52% of the stock of SciSparc is held by insiders.

Percentage Held by Institutions

Only 25.06% of the stock of SciSparc is held by institutions.

SPRC Stock Analysis - Frequently Asked Questions

How have SPRC shares performed this year?

SciSparc's stock was trading at $0.36 on January 1st, 2025. Since then, SPRC shares have increased by 23.9% and is now trading at $0.4460.
View the best growth stocks for 2025 here.

When did SciSparc's stock split?

SciSparc shares reverse split on the morning of Thursday, September 28th 2023. The 1-26 reverse split was announced on Thursday, September 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of SciSparc?

Shares of SPRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of SciSparc own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SciSparc investors own include Solid Power (SLDP), Sangamo Therapeutics (SGMO), Plug Power (PLUG), Mullen Automotive (MULN), NVIDIA (NVDA), Verb Technology (VERB) and Avalon GloboCare (ALBT).

Company Calendar

• Today: 2/22/2025
• Next Earnings (Estimated): 4/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SPRC
• CUSIP: N/A
• CIK: 1611746
• Web: scisparc.com
• Phone: 972-3717-5777
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.86
• Quick Ratio: 1.63

Sales & Book Value

• Annual Sales: $1.75 million
• Price / Sales: 2.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.57 per share
• Price / Book: 0.03

Miscellaneous

• Outstanding Shares: 10,357,000
• Free Float: 10,200,000
• Market Cap: $4.62 million
• Optionable: Not Optionable
• Beta: 0.46